Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C

Köksal, İftihar

doi:10.1111/j.1440-1746.2006.04285.x

Cited by 6 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Turkey, the prevalence of HCV was ranged from 31.4-51% in HD patients at early 2000s (3). Currently, the prevalence of anti-HCV antibody in HD patients in Turkey is 5.2% (4).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Direct-acting Antivirals in Hemodialysis Patients with Chronic Hepatitis C: A Real-life Retrospective Study

Aydın¹,

Aksoy²,

Yavuz³

et al. 2019

vhd

View full text Add to dashboard Cite

Hepatit C virüsü (HCV) enfeksiyonu hemodiyaliz (HD) hastalarında sık görülür ve artmış morbidite ve mortalite ile ilişkilidir. Yeni nesil direkt etkili antiviral (DAA) ajanları, HD hastalarında HCV enfeksiyonunun tedavisinde güvenli ve etkilidir. Bu çok merkezli çalışmada, HCV enfeksiyonu olan HD hastalarında DAA'nın etkinliğini değerlendirmeyi amaçladık. Gereç ve Yöntemler: Bu retrospektif kohort çalışmaya beş merkezde HCV enfeksiyonu ile takip edilen HD hastaları dahil edildi. Hastaların demografik ve virolojik özellikleri, karaciğer fibroz durumu, tedavinin sona ermesi ve tedaviden 12 hafta sonra kalıcı virolojik yanıtlar (SVR12) kaydedildi. Hastaların tedavisi kılavuz ilkeleri göz önünde bulundurularak genotip ve ilaç etkileşimlerine göre düzenlendi. Bulgular: Yirmi hastanın %90'ı genotip 1b idi ve 12 hafta boyunca paritaprevir-ritonavir-ombitasvir-dasabuvir (PrOD) ile tedavi edildi, bir hasta genotip 4 idi ve 12 hafta boyunca PrOD + ribavirin (RBV) aldı, ve bir hasta genotip 3 idi ve 24 hafta boyunca sofosbuvir + RBV ile tedavi edildi. Tedavi sonunda tüm hastalarda HCV-RNA negatifliği sağlandı ve SVR12 oranı %100 idi. Bir hastada uykusuzluk, diğerinde kaşıntı dışında hiçbir hastada önemli yan etkiler gözlenmedi. Sonuç: Gerçek yaşam verilerimiz, HCV'li HD hastalarında yeni nesil DAA'ların yüksek SVR sağladığını ve iyi tolere edildiğini desteklemektedir. Bu hastalarda, DAA rejiminin kesilmesini gerektiren intolerans ve yan etkiler gözlenmedi. Anahtar Kelimeler: Hepatit C, hemodiyaliz, direk etkili antiviral ajan Objectives: Hepatitis C virus (HCV) infection is common among hemodialysis (HD) patients and is associated with increased morbidity and mortality. New generation direct-acting antiviral (DAA) agents are safe and effective in treatment HCV infection in HD patients. The aim of this a multi-center study was to assess the efficacy of DAAs in HD patients with HCV infection. Materials and Methods: HD patients with HCV infection followedup at five centers were included in this retrospective cohort study. Patients demographic and virological characteristics, liver fibrosis status, end of treatment and sustained virologic responses (SVR12) at 12 weeks after treatment were recorded. Treatment of the patients was arranged according to the genotype and drug interactions considering guidelines. Results: Ninety percent of 20 patients were genotype 1b and were treated for 12 weeks with paritaprevir-ritonavir-ombitasvir-dasabuvir; one patient was genotype 4 and received PrOD + ribavirin (RBV) for 12 weeks; and one patient was genotype 3 and was treated with sofosbuvir + RBV for 24 weeks. HCV-RNA negativity was achieved in all patients at the end of treatment and SVR12 rate was 100%. Significant side effects were not observed in any patients, apart from sleeplessness in one patient and itching in another. Conclusion: Our real-life data support that new generation DAAs achieve high SVR and are well tolerated in HD patients with HCV. In these patients, intolerance and side effects were not observed, which would otherwise...

show abstract

“…In Turkey, the prevalence of HCV was ranged from 31.4-51% in HD patients at early 2000s (3). Currently, the prevalence of anti-HCV antibody in HD patients in Turkey is 5.2% (4).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Direct-acting Antivirals in Hemodialysis Patients with Chronic Hepatitis C: A Real-life Retrospective Study

Aydın¹,

Aksoy²,

Yavuz³

et al. 2019

vhd

View full text Add to dashboard Cite

show abstract

“…The prevalence of anti-HCV positivity in hemodialysis patients cited by the Turkish Association for the Fight against Viral Hepatitis is 41.5% [8] while the Turkish Society of Nephrology reports a fıgure of 21.3% [9]. Köksal [10] reported an anti-HCV positivity rate of 31.4-51% in dialysis patients. However, anti-HCV (+) rates in kidney disease patients in Turkey have decreased significantly in recent years, with the Turkish Society of Nephrology reporting a figure of 6.64% at the end of 2014 [11].…”

Section: Introductionmentioning

confidence: 99%

Management of hepatitis C patients with kidney failure

Parlak

2019

Ortadogu Tıp Derg

View full text Add to dashboard Cite

Chronic hepatitis C (CHC) infection is a significant health problem that affects 185 million people worldwide. Complications such as fibrosis, cirrhosis, liver failure and liver cancer may also develop. The hepatitis C virus (HCV) may also progress with non-hepatic involvement. At least one extrahepatic manifestation (EHM) is observed in two out of three of these patients. EHMs may not always be seen together with liver disease findings, and may even appear before clinical chronic viral hepatitis findings. HCV can be diagnosed earlier by means of careful systematic examination. EHMs such as kidney diseases, autoimmune diseases, hematological diseases, diabetes and cardiomyopathy may be encountered in chronic HCV. EHMs can cause morbidity and mortality. Contemporary effective, oral, direct-acting antiviral (DAA) drugs are the first-choice medications. Sustained virological response (SVR) and a high success rate can be achieved in HCV patients with access to these drugs. This report discusses the current status of HCV infection, EHMs, and the available therapeutic options in the treatment of renal failure.

show abstract

“…Pegylated interferons have been more efficient in treatment of chronic HCV infection than standard interferons [21] . However, data on the efficacy and safety of peginterferons in the dialysis population are limited ( table 2 ).…”

Section: Pegylated Interferonmentioning

confidence: 99%

Hepatitis C in Dialysed Patients – What Is the Current Optimal Treatment?

Kes

Bašić‐Jukić²

2007

Kidney Blood Press Res

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in the dialysis population. The problem is more pronounced after renal transplantation. It seems that immunosuppressive drugs facilitate HCV replication and accelerate hepatic lesions. Interferon is not recommended after renal transplantation because of the risk of acute rejection and graft dysfunction, and for this reason it is important to eradicate HCV RNA before transplantation. Prevention is the most important treatment measure. Good clinical practice together with screening of blood products and organs is of outstanding importance. Pegylated interferon (PEG-INF) and ribavirin are currently considered to be optimal therapy for HCV infection. Pegylation delays clearance of interferon, which leads to a more potent and longer antiviral effect. The two PEG-INF formulations (alfa-2a and alfa-2b) with different pharmacokinetic characteristics are currently available. Their clearance is reduced by almost 45% in patients with end-stage renal disease. Taken together with the high prevalence of adverse effects associated with the PEG-INF, an increased awareness of their use in dialysis patients is reasonable. There are few published studies on interferon and PEG-INF therapy in uremic patients. These studies confirm that the rate of response to different interferon formulations in dialysis is much higher than in the general population, but with a higher rate of adverse events. Ribavirin increases the response rate to treatment with PEG-INF. Great caution is warranted on its use in dialysis patients, whereas in patients with renal disease it accumulates and causes a dose-related haemolysis. Current results are encouraging but limited by a small number of patients and short follow-up. Multi-centre, controlled studies with longer follow-up are needed to establish an optimal protocol for the treatment of chronic HCV infection in dialysis patients.

show abstract

Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C

Cited by 6 publications

References 29 publications

Efficacy of Direct-acting Antivirals in Hemodialysis Patients with Chronic Hepatitis C: A Real-life Retrospective Study

Efficacy of Direct-acting Antivirals in Hemodialysis Patients with Chronic Hepatitis C: A Real-life Retrospective Study

Management of hepatitis C patients with kidney failure

Hepatitis C in Dialysed Patients – What Is the Current Optimal Treatment?

Contact Info

Product

Resources

About